Hansoh Pharmaceutical Group Co. Ltd. has announced that its innovative drug, Aumolertinib Mesilate Tablets (trade name in the UK: Aumseqa®), has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom for marketing. Aumseqa® is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, and for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. This approval marks a significant milestone for Hansoh Pharmaceutical as it expands its presence in the UK market with its first innovative third-generation EGFR-TKI drug developed in China.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.